»Call Us 336-396-3916

» Animal Health News & Notes for April 5, 2019

April 5, 2019
Print page

***********************************
Brakke Consulting’s
Animal Health News & Notes for April 5, 2019
Copyright © Brakke Consulting

Editor: Lynn Fondon DVM MBA
************************************
IN THE NEWS:

Brakke Consulting news
Pain Management Products report
Business development and Transaction assistance

earnings news
Cal-Maine

other news
3P Biopharmaceuticals
AgomAb Therapeutics
Alivira
Antelliq
Argenx
Avivagen
Bimeda
Ceva
Clarion Biociênciasin
ECO Animal Health
Intervacc
Merck
NanoSmart Pharmaceuticals
National Veterinary Services
Neogen
Patterson
Phibro
PRN Pharmacal
SourcingLink.net
VetIT
Vetoquinol

***********************************
BRAKKE CONSULTING
2019 PAIN MANAGEMENT PRODUCTS REPORT
PRE-ORDER BY APRIL 19

Pain management is one of the leading topics in veterinary medicine today. Brakke Consulting’s annual report on Pain Management Products for Dogs and Cats includes such valuable information as:
– overview of acute and chronic pain in small animals
– discussion of the impact of the human opioid crisis on veterinary use of opioids
– review of new products
– estimates of US sales and prices of leading products
– pain management products in development
– review of nutritional supplements used for chronic pain
– review of therapeutic diets for joint care
– discussion of the use of cannabinoids in veterinary pain management
– 2019 survey of 300 small animal veterinarians regarding use of pain management products

Pain Management Products for Dogs and Cats 2019 can be purchased for $5,250 if ordered by April 19, 2019, and $5,750 thereafter. The report will be completed in May. Questions about the study can be answered by project manager Lynn Fondon, DVM, MBA at Lfondon@brakkeconsulting.com.

www.BrakkeConsulting.com

***********************************
COMPANY EARNINGS RELEASES

• Cal-Maine reported results for its fiscal 2019 Q3 ended March 2. Net sales were $384 million, a 12% decrease compared to the third quarter of fiscal 2018. Net income was $39.8 million for the third quarter of fiscal 2019, compared to net income of $96.3 million for the third quarter of fiscal 2018 (results for the third quarter of fiscal 2018 were favorably affected by a $35.0 million discrete tax benefit). (Feedstuffs)

**********************************
COMPANY NEWS RELEASES

• Merck announced the completion of its acquisition of Antelliq Corporation from funds advised by BC Partners. The transaction is worth EUR 2.1 billion ($2.37 billion). (company press release, Animal Pharm)

• Bimeda announced the launch of Bimectin Plus (1% ivermectin and 10% clorsulon) Injection for Cattle. Bimectin Plus is labeled for the treatment and control of internal and external parasites of cattle, including gastrointestinal roundworms, lungworms, sucking lice, mange mites, cattle grubs and adult liver flukes. (company press release)

• The FDA announced the approval of Proin ER (phenylpropanolamine hydrochloride extended-release) tablets for the control of urinary incontinence due to urethral sphincter hypotonus in dogs. The product is marketed by Pegasus Laboratories d.b.a. PRN Pharmacal. (FDA)

• Neogen announced it has introduced a portable version of its Raptor Integrated Analysis Platform that provides the option of performing mycotoxin testing in the laboratory — or wherever a tester may choose. As with the original benchtop version, the new Raptor is a lateral flow test strip reader with built-in incubation that provides an easy way to objectively analyze and store results of Neogen’s Reveal Q+ MAX lateral flow tests. (company press release)

• Avivagen Inc. announced that it has begun to explore the combination of Avivagen’s proprietary OxC-beta product with licensed cannabis products. (company press release)

• SourcingLink.net, Inc. announced an exclusive, worldwide licensing agreement with NanoSmart Pharmaceuticals, Inc for the right to use NanoSmart’s Anti-Nuclear Antibody (ANA)-targeted drug delivery technologies to develop and commercialize chemotherapy drug formulations for veterinary oncology. (Globe newswire)

• EU Ceva announced that the European Medicines Agency’s Committee for Medicinal Products for Veterinary Use (CVMP) has recommended a change in the legal status of Vectra 3D (dinotefuran, permethrin and pyriproxyfen), which is currently a prescription only product, to become a non-prescription veterinary medicine. Vectra 3D is a spot-on solution for dogs for the treatment and prevention of flea, tick, sand fly, mosquito and stable fly infestations. (Animal Pharm)

• BRAZIL Vetoquinol announced an agreement to acquire Brazilian veterinary laboratory Clarion Biociênciasin. The acquisition will offer Vetoquinol the opportunity to reinforce its position in the Brazilian animal health market, primarily in the cattle sector. Financial terms were not disclosed. (Animal Pharm)

• EU Phibro Animal Health announced it was awarded a European patent for its OmniGen feed supplement. OmniGen helps dairy producers prepare for the impacts of heat stress on their herds. (APNews)

• UK Patterson Companies, Inc. announced the company has agreed to acquire VetIT, a cloud-based veterinary practice management solution based in the United Kingdom. The new acquisition will fall under National Veterinary Services (NVS), a subsidiary of Patterson. Financial terms were not disclosed. (Vet Advantage)

• EU ECO Animal Health announced that it has received a marketing authorization from the European Medicines Agency (EMA) for the use of Aivlosin 625 mg/g Water Soluble Granules (WSG) in breeding chickens for the treatment and metaphylaxis of respiratory infections caused by Mycoplasma gallisepticum. (company press release)

• FRANCE Alivira announced the launch of Robonex Pour On, an eprinomectin-based pour-on for Cattle in France. (company press release)

• EU Intervacc announced it has secured an agreement with Spanish firm 3P Biopharmaceuticals for the mass production of Intervacc’s Strangvac vaccine against equine strangles. Intervacc intends to submit a European registration application for Strangvac by the end of 2019, with full commercialization expected in 2020. (Animal Pharm)

• EU Belgian firm AgomAb Therapeutics announced a EUR 21 million ($23.5 million) series A round to develop agonistic monoclonal antibodies (“agomAbs”) that could potentially treat a variety of diseases. AgomAb has an exclusive license to an antibody platform from Netherlands-based Argenx that is based on the llama immune system. (Fierce Pharma)

***********************************
ANIMAL HEALTH NEWS

• US – VETERINARY INNOVATION Cornell’s College of Veterinary Medicine (CVM) announced the launch of the Center for Veterinary Business and Entrepreneurship (CVBE), a new interdisciplinary program intended to spur research, training and outreach in veterinary business to improve animal health care. The program unites expertise from CVM and the Cornell SC Johnson College of Business. (news.cornell.edu)

• US – ANTIMICROBIAL RESEARCH FUNDING The FDA announced a funding opportunity and Request for Applications (RFA) for studies that can help target and define durations of use for certain medically important antimicrobial drugs approved for use in the feed of food-producing animals. From April 1 to June 1, 2019, the FDA’s Center for Veterinary Medicine (CVM) will accept research applications for the Fiscal Year (FY) 2019 program, which will fund up to $1.5 million in support of applications for studies in FY 2019, with a maximum of $250,000 provided to any individual awardee. For more information, go to https://www.fda.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm634779.htm?utm_campaign=4-1-2019-DurationofUse&utm_medium=email&utm_source=Eloqua (FDA)

• US – CANNABIS REGULATION The FDA announced new steps to advance the agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products. These steps apply to use in humans and animals and involve a public hearing scheduled for May and the formation of a high-level internal agency working group. For more information about the public hearing, go to https://www.federalregister.gov/documents/2019/04/03/2019-06436/scientific-data-and-information-about-products-containing-cannabis-or-cannabis-derived-compounds. (Feedstuffs)

• US – ANIMAL DEPOPULATION GUIDELINES The American Veterinary Medical Association (AVMA) has published its first ever “Guidelines for the Depopulation of Animals” to help veterinarians support animal welfare in situations where the difficult decision to depopulate has been made. The new AVMA guidelines aim to ensure that as much consideration is given to animal welfare as practicable within the constraints of an emergency. (FDA)

• US – ADVERSE EVENT REPORTING The FDA’s Center for Veterinary Medicine (CVM) announced the availability of data from more than 30 years of adverse event reports related to animal drugs and devices used in animals. Previously, CVM said this detailed level of data was only available via a Freedom of Information Act request, but now this information is electronically accessible to the public and available for automated searching at https://open.fda.gov/apis/. (Feedstuffs)

************************************
BRAKKE CONSULTING
BUSINESS DEVELOPMENT AND TRANSACTION ASSISTANCE

Why not let Brakke Consulting provide assistance for all your business development projects? We have insights and information regarding the trends and activities in the marketplace that allows us to provide unique quality services that few other firms can provide. Other firms may indicate that they know the industry, but do they really?

Brakke Consulting has been the finder of record, sales agent of record or consultant for many small and large successfully completed projects. We can assist with valuations and provide due diligence on confidential transactions, as well as offering senior executives insights and input on potential transactions. It’s best to involve Brakke Consulting early in the process so we can help clients avoid costly mistakes.

Brakke Consulting has the hands on experience, market insight, ability and contacts to provide clients with the highest quality services in the animal health, pet, veterinary and specialty chemicals markets. Please contact any of our offices for a confidential consultation.

www.BrakkeConsulting.com

************************************
BRAKKE CONSULTING VIEWPOINT

The first quarter of 2019 is now in the books. Hopefully most companies will be reporting positive revenue and profit results versus prior year in the coming days and weeks. The feedback we’ve been receiving from industry is generally positive and the activity level is high; once the actual numbers are reported for the first three months, we’ll have a clear picture of what is really happening. It does appear – and none too soon – that winter is now behind us in the US, but we would expect the challenging weather of the past few weeks to have a negative impact on revenues for the quarter and the year.

Like most weeks, several of the stories this week reflect the continued investment and consolidation in the industry. We’re pleased to say that Brakke Consulting has been, and continues to be, an active participant in the business development area for both large and small clients. We are currently managing a number of different business development projects for clients that will have a positive impact on the industry when they are completed. Since the founding of the firm, Brakke Consulting has been involved in over 60 transactions not including a many due diligence projects. Give us a call and let us assist in this important area of growth for your company.

Have a great weekend!

Ron Brakke

**********************************
This electronic newsletter is the sole property of Brakke Consulting.
Any use of the contents herein should be approved by and appropriately attributed to Brakke Consulting.

For more information about Brakke Consulting’s services and syndicated studies, visit our website at www.brakkeconsulting.com.

Brakke Consulting
806 Green Valley Rd
Suite 200
Greensboro, NC 27408